Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key COVID-19 Studies Influencing My Practice Following IDWeek 2022—Audio Recap

Source: CCO Independent Conference Coverage of IDWeek 2022: Clinical Impact of New COVID-19 Data*
October 19-23, 2022; Washington, DC
Listen to expert insights from Princy N. Kumar, MD, and Paul E. Sax, MD, on updates and new COVID-19 data from IDWeek 2022, including data on vaccines, risk factors and risk stratification, diagnostics, therapeutics, treatment of patients with immunocompromise, and long COVID.
Princy N. Kumar, MD, FIDSA, MACP
Paul E. Sax, MD
Released: November 18, 2022

In this episode, Princy N. Kumar, MD, and Paul E. Sax, MD, discuss new COVID-19 data from IDWeek 2022, including:

  • COVID-19 vaccines, including omicron BA.1 bivalent booster
  • Risk factors for breakthrough COVID-19 infections
  • COVID-19 diagnostics, including digital droplet PCR
  • COVID-19 therapeutics, including:
    • Nirmatrelvir plus ritonavir
    • Tixagevimab plus cilgavimab
    • Baricitinib
    • Tocilizumab
    • Inhaled interferon β-1a
  • COVID-19 therapeutics and outcomes in patients with immunocompromise
  • Long COVID

Information on this Educational Activity

Faculty

Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP: researcher: American Gene Technologies, Gilead Sciences, GlaxoSmithKline, Merck; advisor: Gilead Sciences, Johnson & Johnson, Merck, Theratechnologies, ViiV; ownership interest: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer.
Paul E. Sax, MD

Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul E. Sax, MD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline/ViiV, Janssen; researcher: Gilead Sciences, GlaxoSmithKline/ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.

Related Content

This downloadable PDF reviews a treatment pathway for nonhospitalized patients with COVID-19, from Clinical Care Options (CCO), Practicing Clinicians Exchange (PCE), and ProCE

Renslow Sherer, MD Released: January 17, 2023

Dr Stephaun Elite Wallace on COVID-19 inequities in BIPOC communities and strategies to minimize these disparities, from Clinical Care Options (CCO), Practicing Clinicians Exchange (PCE), and ProCE

Stephaun Elite Wallace, PhD, MS Released: January 17, 2023

Clinical Care Options (CCO) podcast with Drs. Jens Lundgren and Barbara Rath on acute COVID-19 and long COVID in Europe.

Jens D. Lundgren, MD, DMSc Barbara Rath, MD, PhD, HDR Released: January 13, 2023

Drs Jens Lundgren and Barbara Rath on acute COVID-19 and long COVID in Europe, from Clinical Care Options (CCO)

Jens D. Lundgren, MD, DMSc Barbara Rath, MD, PhD, HDR Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Released: January 11, 2023 Expired: January 10, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings